Resultats de la cerca - Young‐Hyuck Im

Refinar resultats
  1. 1
    Cytokine profiling in serum-derived exosomes isolated by different methods

    Cytokine profiling in serum-derived exosomes isolated by different methods per Hae Hyun Jung, Ji‐Yeon Kim, Ji Eun Lim, Young‐Hyuck Im

    Publicat 2020
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  2. 2
    <scp><i>TP53</i></scp> mutations predict poor response to immunotherapy in patients with metastatic solid tumors

    <scp><i>TP53</i></scp> mutations predict poor response to immunotherapy in patients with metastatic solid tumors per Ji‐Yeon Kim, Sun-Young Jung, Kyoung‐Mee Kim, Jeeyun Lee, Young‐Hyuck Im

    Publicat 2023
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  3. 3
    Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA

    Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomi... per Sandra M. Swain, José Baselga, David Miles, Young‐Hyuck Im, Cheng S. Quah, L.F. Lee, Javier Cortés

    Publicat 2014
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  4. 4
    Multimodal deep learning models for the prediction of pathologic response to neoadjuvant chemotherapy in breast cancer

    Multimodal deep learning models for the prediction of pathologic response to neoadjuvant chemotherapy in breast cancer per Sunghoon Joo, Eun Sook Ko, Soonhwan Kwon, Eunjoo Jeon, Hyungsik Jung, Ji‐Yeon Kim, Myung Jin Chung, Young‐Hyuck Im

    Publicat 2021
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  5. 5
    Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer

    Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer per Javier Cortés, José Baselga, Young‐Hyuck Im, Sang-Jun Im, Xavier Pivot, G. Ross, Emma Clark, A Knott, Sandra M. Swain

    Publicat 2013
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  6. 6
    Safety Profile of Pertuzumab With Trastuzumab and Docetaxel in Patients From Asia With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Results From the Phase III Trial CLEOPATRA

    Safety Profile of Pertuzumab With Trastuzumab and Docetaxel in Patients From Asia With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Results From the... per Sandra M. Swain, Young‐Hyuck Im, Seock‐Ah Im, Valorie F. Chan, David Miles, Adam Knott, Emma Clark, Graham Ross, José Baselga

    Publicat 2014
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  7. 7
    Association between Socioeconomic Status and Altered Appearance Distress, Body Image, and Quality of Life Among Breast Cancer Patients

    Association between Socioeconomic Status and Altered Appearance Distress, Body Image, and Quality of Life Among Breast Cancer Patients per Oliver Chang, Eun‐Kyung Choi, Nayeon Kim, Seok Jin Nam, Jeong Eon Lee, Se Kyung Lee, Young‐Hyuck Im, Winnie Yeo, Juhee Cho

    Publicat 2014
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  8. 8
    Ribociclib (RIB) + tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) in premenopausal patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC): MONALEESA-7 patient-reported outcomes (PROs)

    Ribociclib (RIB) + tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) in premenopausal patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2–) advance... per Nadia Harbeck, Rafael Sánchez, F. Franke, Govind Babu, Paul Wheatley‐Price, Young‐Hyuck Im, Kadri Altundağ, Brad Lanoue, Jahangir Alam, David Chandiwana, Marco Colleoni

    Publicat 2018
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  9. 9
    Transcriptional repression of the transforming growth factor-β type I receptor gene by DNA methylation results in the development of TGF-β resistance in human gastric cancer

    Transcriptional repression of the transforming growth factor-β type I receptor gene by DNA methylation results in the development of TGF-β resistance in human gastric cancer per Shin Hyeok Kang, Yung‐Jue Bang, Young‐Hyuck Im, Han-Kwang Yang, David A. Lee, Hwa Young Lee, Ho Soon Lee, Noe Kyeong Kim, Seong‐Jin Kim

    Publicat 1999
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  10. 10
    Phase II DORA Study of Olaparib with or without Durvalumab as a Chemotherapy-Free Maintenance Strategy in Platinum-Pretreated Advanced Triple-Negative Breast Cancer

    Phase II DORA Study of Olaparib with or without Durvalumab as a Chemotherapy-Free Maintenance Strategy in Platinum-Pretreated Advanced Triple-Negative Breast Cancer per Tira J. Tan, Sarah Sammons, Young‐Hyuck Im, Lilin She, Kelly Mundy, Robert Bigelow, Tiffany A. Traina, Carey K. Anders, Joe Yeong, Ezequiel Renzulli, Sung‐Bae Kim, Rebecca Dent

    Publicat 2024
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  11. 11
    The relationship between nuclear factor (NF)-κB family gene expression and prognosis in triple-negative breast cancer (TNBC) patients receiving adjuvant doxorubicin treatment

    The relationship between nuclear factor (NF)-κB family gene expression and prognosis in triple-negative breast cancer (TNBC) patients receiving adjuvant doxorubicin treatment per Ji‐Yeon Kim, Hae Hyun Jung, Soomin Ahn, SooYoun Bae, Se Kyung Lee, Seok Won Kim, Joon Jeong, Seok Jin Nam, Jin Seok Ahn, Young‐Hyuck Im, Yeon Hee Park

    Publicat 2016
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  12. 12
    Clinical implication of tumor mutational burden in patients with HER2-positive refractory metastatic breast cancer

    Clinical implication of tumor mutational burden in patients with HER2-positive refractory metastatic breast cancer per Song Ee Park, Kyunghee Park, Eunjin Lee, Ji‐Yeon Kim, Jin Seok Ahn, Young‐Hyuck Im, Choonghoon Lee, Hun Jung, Soo Youn Cho, Woong‐Yang Park, Rǎzvan Cristescu, Yeon Hee Park

    Publicat 2018
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  13. 13
    Prognostic value of ERBB4 expression in patients with triple negative breast cancer

    Prognostic value of ERBB4 expression in patients with triple negative breast cancer per Ji‐Yeon Kim, Hae Hyun Jung, In‐Gu Do, SooYoun Bae, Se Kyung Lee, Seok Won Kim, Jeong Eon Lee, Seok Jin Nam, Jin Seok Ahn, Yeon Hee Park, Young‐Hyuck Im

    Publicat 2016
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  14. 14
    Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: results from a phase III randomized clinical trial (MONALEESA-7)

    Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: results f... per Nadia Harbeck, Fábio Franke, Rafael Villanueva-Vázquez, Yen‐Shen Lu, Debu Tripathy, Louis WC Chow, Govind K Babu, Young‐Hyuck Im, David Chandiwana, Anil Gaur, Brad Lanoue, Karen Rodriguez-Lorenc, Aditya Bardia

    Publicat 2020
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  15. 15
    Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer

    Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer per José Baselga, Javier Cortés, Sung‐Bae Kim, Seock‐Ah Im, Roberto Hegg, Young‐Hyuck Im, Laslo Roman, José Luiz Pedrini, Tadeusz Pieńkowski, Adam Knott, Emma Clark, Mark Benyunes, Graham Ross, Sandra M. Swain

    Publicat 2011
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  16. 16
    Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2–Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study

    Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2–Positive, Advanced Breast Cancer: Primary Results From... per Edith A. Perez, Carlos H. Barrios, W. Eiermann, Masakazu Toi, Young‐Hyuck Im, Pierfranco Conté, Miguel Martín, Tadeusz Pieńkowski, Xavier Pivot, Howard A. Burris, Jennifer Petersen, S Stanzel, Alexander Strasak, Monika Patre, Peter Ellis

    Publicat 2017
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  17. 17
    Clinical Features and Outcomes of Invasive Breast Cancer: Age-Specific Analysis of a Modern Hospital-Based Registry

    Clinical Features and Outcomes of Invasive Breast Cancer: Age-Specific Analysis of a Modern Hospital-Based Registry per Ji‐Yeon Kim, Danbee Kang, Seok Jin Nam, Seok Won Kim, Jeong Eon Lee, Jong Han Yu, Se Kyung Lee, Young‐Hyuck Im, Jin Seok Ahn, Eliseo Güallar, Juhee Cho, Yeon Hee Park

    Publicat 2019
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  18. 18
    Implications of Bone-Only Metastases in Breast Cancer: Favorable Preference with Excellent Outcomes of Hormone Receptor Positive Breast Cancer

    Implications of Bone-Only Metastases in Breast Cancer: Favorable Preference with Excellent Outcomes of Hormone Receptor Positive Breast Cancer per Su Jin Lee, Silvia Park, Hee Kyung Ahn, Jun Ho Yi, Eun Yoon Cho, Jong Mu Sun, Jeong Eon Lee, Seok Jin Nam, Jung-Hyun Yang, Winnie Yeo, Jin Seok Ahn, Young‐Hyuck Im

    Publicat 2011
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  19. 19
    Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer

    Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for t... per Giampaolo Bianchini, Astrid Kiermaier, Giulia Bianchi, Young‐Hyuck Im, Tadeusz Pieńkowski, Mei-Ching Liu, Ling‐Ming Tseng, Mitch Dowsett, Lila Zabaglo, S Kirk, Tania Szado, Jennifer Eng‐Wong, Lukas C. Amler, Pinuccia Valagussa, Luca Gianni

    Publicat 2017
    Obtenir text complet Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:
  20. 20
    PALOMA-3: Phase III Trial of Fulvestrant With or Without Palbociclib in Premenopausal and Postmenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That Progressed on Prior Endocrine Therapy—Safety and Efficacy in Asian Patients

    PALOMA-3: Phase III Trial of Fulvestrant With or Without Palbociclib in Premenopausal and Postmenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Recepto... per Hiroji Iwata, Seock‐Ah Im, Norikazu Masuda, Young‐Hyuck Im, Kenichi Inoue, Yoshiaki Rai, Rikiya Nakamura, Jee Hyun Kim, Justin T. Hoffman, Ke Zhang, C. Giorgetti, Shrividya Iyer, Patrick T. Schnell, Cynthia Huang Bartlett, Jungsil Ro

    Publicat 2017
    Obtenir text complet
    Artigo
    Afegir a favorits
    Guardat en:

Eines de cerca: